Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
44 hedge funds and large institutions have $150M invested in Mirati Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
7% more capital invested
Capital invested by funds: $140M → $150M (+$9.47M)
2% more funds holding
Funds holding: 43 → 44 (+1)
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.14M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$474K |
| 3 |
BI
Boulegeris Investments
Sandy Springs,
Georgia
|
+$187K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$132K |
| 5 |
Morgan Stanley
New York
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$843K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$489K |
| 3 |
Goldman Sachs
New York
|
-$158K |
| 4 |
JP Morgan Chase
New York
|
-$72.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$59.5K |
MRTX Hedge Fund Activity: Q4 2014 in Review
44 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2014, worth a combined $150M — up 6.7% from $140M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MRTX positions and 2 closed out — a net gain of 3 holders — while 14 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.14M. The largest seller was Tang Capital Management, cutting an estimated $843K.
- 44 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2014, up from 43 in Q3 2014.
- Funds reported $150M of Mirati Therapeutics, Inc. Common Stock stock for Q4 2014, up 6.7% quarter-over-quarter.
- 5 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2014 and 2 closed out, a net change of +3 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2014 was Fidelity Investments, an estimated $1.14M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2014 was Tang Capital Management, an estimated $843K sold.
Based on aggregated 13F filings for Q4 2014.